Skip Navigation


JAC Advance Access originally published online on October 28, 2006
Journal of Antimicrobial Chemotherapy 2007 59(1):157-159; doi:10.1093/jac/dkl430
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
59/1/157-a    most recent
dkl430v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rajagopalan, G.
Right arrow Articles by David, C. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rajagopalan, G.
Right arrow Articles by David, C. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Correspondence

Comment on: Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation

Govindarajan Rajagopalan1,*, Robin Patel2, Srini V. Kaveri3 and Chella S. David1

1 Department of Immunology, Mayo Clinic College of Medicine 200 First Street, SW, Rochester, MN 55905, USA 2 Divisions of Infectious Diseases and Clinical Microbiology, Mayo Clinic College of Medicine Rochester, MN 55905, USA 3 INSERM Unité 681 and Université Pierre et Marie Curie, Institut des Cordeliers Paris, France

*Corresponding author. Tel: +1-507-284-8180; Fax: +1-507-266-0981; E-mail: rajagopalan.govindarajan@mayo.edu

Keywords: superantigens , IVIg , HLA class II transgenic mice

The first 10% of the full text of this article appears below.

Sir,

In a recent report, Sriskandan et al.,1 evaluated human intravenous immunoglobulin (IVIg) in streptococcal toxic shock using the HLA-DQ8 transgenic mouse model. They observed that human IVIg neutralized streptococcal superantigens in vitro as well as in vivo and concluded that human IVIg could have potential therapeutic benefit in streptococcal toxic shock syndrome.1 Using a similar system we have observed that IVIg did not neutralize purified streptococcal superantigen-induced lymphocyte proliferation in vitro as well as in vivo. While Sriskandan et al.1 used streptococcal bacterial culture supernatants as the source of bacterial superantigens, we used purified individual streptococcal bacterial superantigens for our . . . [Full Text of this Article]

Transparency declarations


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?